Book Value per Share: kairospharma.com (KAPA)

Public company logo of Kairos Pharma Ltd (KAPA)

The lack of profitability and dependence on test results create significant risks for Kairos Pharma Ltd (KAPA). The development of targeted therapy serves as the primary growth driver. The book value per share helps assess financial strength, with 1.38 representing the current value of this metric. Kairos Pharma Ltd (KAPA) relies on cooperation with leading clinics to create innovative methods for combating tumor resistance.

Kairos Pharma Inc (KAPA) - Accounting Value per Share from 09/17/2024 to 10/28/2026

Summary analytical data breakdowns for Kairos Pharma Limited (KAPA)

- price and consensus price forecast:
Price Chart Kairos Pharma Inc|KAPA - Forecast Levels Chart
- market capitalization data:
Market Capitalization Kairos Pharma Ltd|KAPA - Enterprise Value
- book capitalization data:
Book Value per Share Kairos Pharma|KAPA - Company Net Assets|Market Capitalization to Book Value Ratio kairospharma.com|KAPA - Company Total Assets
- debt and liquidity data:
Debt to Equity Kairos Pharma Ltd|KAPA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Kairos Pharma Inc|KAPA - Company Total Debt|Debts to Book Capitalization Kairos Pharma Ltd|KAPA - Long-Term Debt|Company Short-Term Debt Kairos Pharma
Analysis of all company metrics:kairospharma.com, KAPA
Manufactured product of Kairos Pharma Limited

Costly clinical trials and patent protection for oncological therapies define the asset structure of Kairos Pharma Ltd. The current value of 1.38 on the book value chart per ordinary share reflects net equity minus liabilities, measuring the company's real asset safety margin, where high capital protection may indicate both stability and the risk of low investment efficiency.

Competitor analysis for Kairos Pharma Ltd

Net Assets per Single Share BeiGene Corp|HALO - Share Book Value|RVMD: Book Value per Share|ascentage.com (AAPG) - Book Value per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OSTX|Net Assets per Single Share RADX|Book Value per Share artivabio.com (ARTV)|Book Value per Share ANL (Adlai Nortye)|Book Value per Share Veru Inc VERU|Book Value per Share TPST (Tempest Tx)|XLO: Net Assets per Share|Net Assets per Single Share renovarobio.com RENB|MURA (Mural Oncology) - Accounting Value of a Share|Net Assets per Single Share OKUR (OnKure Therapeutics, Inc.)|Net Asset Value per Share GDTC|CRIS (Curis, Inc.) - Net Assets per Single Share|Net Assets per Share apollomicsinc.com APLM|Accounting Value per Share Tharimmune, Inc.|Advanced Biomed Inc. - Accounting Value of a Share|Net Assets per Single Share Genprex|CLDI - Share Book Value|Book Value per Share Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences, Inc. (XBIO) - Accounting Value of a Share|SLRX (Salarius Pharmaceuticals) - Book Value per Share|Book Value per Share PPBT|American Oncology Network (AONC) - Net Assets per Single Share|Accounting Value of a Share BGNE (BeiGene Ltd.)|Checkpoint Therapeutics, Inc - Net Assets per Single Share|Accounting Value per Share elevationoncology.com ELEV|iCAD Corp - Book Value per Share|Ikena Oncology, Inc. (IKNA) - Book Value per Share|Accounting Value per Share Notable Labs NTBL|VIRX (Viracta Therapeutics, Inc.) - Accounting Value of a Share|Net Assets per Single Share MorphoSys Corp|Net Assets per Single Share NAYA Biosciences Corp (NAYA)|Accounting Value per Share Ascentage Pharma Group